Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications by BOSCOLO RIZZO, Paolo et al.
Original Citation:
Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical
implications
Springer
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3195733 since: 2017-02-09T11:55:55Z
10.1007/s10555-016-9633-1
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
CLINICAL
Telomeres and telomerase in head and neck squamous cell
carcinoma: from pathogenesis to clinical implications
Paolo Boscolo-Rizzo1 & Maria Cristina Da Mosto1 & Enrica Rampazzo2 & Silvia Giunco2 &
Annarosa Del Mistro3 & Anna Menegaldo1 & Lorena Baboci3 & Monica Mantovani1 &
Giancarlo Tirelli4 & Anita De Rossi2,3
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Strongly associated with tobacco use, heavy alco-
hol consumption, and with high-risk human papillomavirus
(HPV) infection, head and neck squamous cell carcinoma
(HNSCC) is a frequently lethal, heterogeneous disease whose
pathogenesis is a multistep and multifactorial process involv-
ing genetic and epigenetic events. The majority of HNSCC
patients present with locoregional advanced stage disease and
are treated with combined modality strategies that can mark-
edly impair quality of life and elicit unpredictable results. A
large fraction of those who undergo locoregional treatment
and achieve a complete response later develop locoregional
recurrences or second field tumors. Biomarkers that are thus
able to stratify risk and enable clinicians to tailor treatment
plans and to personalize post-therapeutic surveillance strate-
gies are highly desirable. To date, only HPV status is consid-
ered a reliable independent predictor of treatment response
and survival in patients with HNSCC arising from the oropha-
ryngeal site. Recent studies suggest that telomere attrition,
which may be an early event in human carcinogenesis, and
telomerase activation, which is detected in up to 90 % of
malignancies, could be potential markers of cancer risk and
disease outcome. This review examines the current state of
knowledge on and discusses the implications linked to telo-
mere dysfunction and telomerase activation in the develop-
ment and clinical outcome of HNSCC.
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1 Introduction
Head and neck cancer was expected to affect approximately
742,000 and 144,000 new patients, worldwide and in Europe,
respectively, in 2015 [1]. The most common type of head and
neck cancer is head and neck squamous cell carcinoma
(HNSCC) which is a morbid, frequently lethal disease that
develops in the epithelial cell lining of the upper aero-
digestive tract (UADT, i.e., the oral cavity, pharynx, and lar-
ynx) [2]. While it has been strongly associated with tobacco
use and heavy alcohol consumption, over the past two decades,
high-risk alpha human papillomaviruses (HR α-HPV) have
emerged as an important etiological factor for a subset of
HNSCC arising from the oropharynx [3, 4]. The prevalence
of HPV-driven HNSCC has been dramatically increasing in
developed countries, predominantly affecting males at a youn-
ger age that those with tobacco- and alcohol-related carcino-
mas, and changes considerably across different geographical
areas [5–7]. HPV-driven HNSCC and tobacco- and alcohol-
related HNSCC are two biologically and clinically distinct
entities [6, 8–14].
Primarily a locoregional disease at presentation [2], HNSCC
frequently spreads to the neck lymph nodes, an event that usu-
ally occurs before it metastasizes to distant organs.
Approximately one third of patients present with early stage
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squamous cell carcinoma (SCC) (small primary tumors with no
evidence of lymph node metastases). This prognostically fa-
vored subgroup is generally treated with a single-modality ap-
proach consisting in surgery or radiotherapy alone, with cure
rates reaching up to 90 % [15]. Most HNSCCs present, how-
ever, at an advanced stage, with the majority of patients facing
combined modality therapy consisting in surgery followed by
adjuvant radio-(chemo)therapy or upfront chemoradiotherapy
with salvage surgery in non-responders [16, 17]. The extraor-
dinary advancements in treatment strategies have not as yet
produced the hoped for cure rates [18]; regrettably, the majority
of HNSCC patients who show a complete response to
locoregional treatment later develop locoregional recurrence,
and approximately 35 and 30 %, respectively, develop distant
metastases or second primary tumors of the UADT, lung, or
esophagus [19, 20]. The median survival in patients with inop-
erable recurrent or metastatic disease is only 10months in those
receiving the best established chemotherapy regimen [21].
Intensive treatment strategies for locoregional advanced dis-
ease such as sequential or concurrent chemotherapy in addition
to locoregional treatment, taxane-platinum combination che-
motherapy regimens, and altered fractionation radiotherapy
protocols have yielded encouraging results, although at the
expense of substantial acute and late toxicity [22–24].
Traditional prognostic factors such as overall stage and
neck metastases at presentation seem to have limited predic-
tion accuracy and reproducibility [25]. In an era of biomarker-
driven personalized cancer therapy, several investigations are
currently examining new biological markers as prognostic and
predictive factors in HNSCC [26]. But with the exception of
positivity to HPV and its surrogate cyclin-dependent kinase
inhibitor p16INK4a, no other prognostic biomarkers are pres-
ently being used in routine clinical practice in head and neck
oncology [27].
HNSCC is a heterogeneous disease whose pathogenesis is
a multistep, multifactorial process involving genetic and epi-
genetic aberrations [28]. Invasive HNSCC may be clinically
preceded by visible pre-neoplastic lesions often appearing as
white patches, particularly common in the oral cavity and
larynx [29], exhibiting an annual transformation rate exceed-
ing 3 % [30]. Termed leukoplakia, these white patches may
harbor hyperplastic or dysplastic epithelial lesions and their
molecular characterization may quantify the risk of transfor-
mation [31]. Genetic alterations in pre-neoplastic lesions of
the UADT may reflect aberrations in cellular differentiation
or cell cycle control. Suprabasal expression of low molecular
weight keratins [29], loss of heterozygosity of the TP53 gene
[32], microsatellite instability [33], and higher chromosomal
aneuploidy rates [34] all increase the risk of malignant trans-
formation. Unfortunately, several pre-neoplastic lesions in the
UADT are not clinically detectable.
Slaughter et al. first formulated the theory of “field
cancerization” in 1953 [35] to explain high recurrence rates
following tumor resections or UADT metachronous second
primary tumors in patients treated for HNSCC. According to
this model, the emergence of malignant lesions is preceded by
the development of precancerous fields characterized by ge-
netic alterations linked to carcinogen exposure. Following
crucial genetic hits, a cell within the field can become cancer-
ous and eventually give rise to invasive SCC. The risk of a
second tumor is, moreover, markedly higher in cases in which
this more-prone-to-transformation mucosa partially persists
after the primary tumor has been treated, and this mechanism
has recently been described in molecular terms [36, 37].
Clusters of cells with cancer-associated genetic alterations
such as TP53 mutations have been detected in biopsies of
histologically normal mucosa of HNSCC patients, and, in
particular, in those with multiple primary malignancies [38].
Proteomic analysis has recently detected abnormal proteomic
profiling in tumor-adjacent and tumor-distant UADT mucosa
samples without histological aberrations [39]. Identifying
markers of field cancerization could, therefore, hold promise
for improving risk assessment and personalized post-therapy
surveillance in HNSCC patients.
Recent whole-exome sequencing studies have painted new
pictures of the genetic landscape of HNSCC and have uncov-
ered unexpected therapeutic targets [40]. HNSCC’s mutational
landscape is dominated by tumor suppressor genes with activat-
ing oncogene mutations playing an additional relevant role
[41–43]. TP53, CDKN2A, CCND1, PIK3CA, and NOTCH1
are the most commonly mutated genes in HNSCC.
Telomerase reverse transcriptase (TERT) promoter mutations
resulting in increased telomerase expression have also been
detected in a significant proportion of HNSCCpatients [44–46].
The tumor suppressor p53 protein and the retinoblastoma
(RB) tumor suppressor protein pathways are the most fre-
quently deregulated signaling pathways in HNSCC [47].
Since activated p53 triggers the expression of several genes
involved in cell cycle arrest, DNA repair, or apoptosis, it plays
a crucial role in tumor suppression [48]. RB inhibits E2F
transcription factor by direct protein-protein interactions thus
preventing transition to the S phase of the cell cycle and pro-
moting cell cycle arrest in G1 [49].
Most HPV-negative tumors harbor inactivating mutations
in the TP53 gene [50]. In HNSCC with wild-type TP53, the
protein may be inactivated by binding to the HPV E6
oncoprotein or to the cellular over-expressed MDM2 onco-
gene. Overall, the p53 pathway is down-regulated in at least
80 % of HNSCC [2].
The p16INK4a-cyclin D1-RB axis is also frequently
deregulated in HNSCC. HPV-negative HNSCC show inacti-
vation mainly by deletion or promoter hypermethylation of
the CDKN2A gene encoding p16INK4a [51] and frequently
have CCND1 amplification [52], which encodes cyclin D1,
with both leading to a decrease in the growth-suppressive
hypo-phosphorylated RB form.
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In HPV-driven HNSCC, the p53 and RB pathways are both
inactivated at the protein level. The E6 protein promotes cell
proliferation by stimulating ubiquitination and proteasome-
dependent degradation of the p53 protein via the formation
of a trimeric complex including E6, p53, and the cellular ubiq-
uitin ligase E6AP. In addition to targeting p53, HR α-HPV E6
activates telomerase [53]. E7 viral oncoprotein targets the RB/
E2F complex, resulting in the dissociation of RB-family pro-
teins from E2F transcription factors and inducing S phase
entry [54]. HPV-driven HNSCC shows, moreover, a higher
incidence of activating mutations in the PIK3CA gene, fewer
gross chromosomal aberrations, and approximately one half
the mutation rate of its HPV-negative counterparts [43]. In
addition, vascular endothelial growth factor (VEGF)-C and
VEGF receptor 3 are involved in the molecular pathways that
lead to newly formed intra- and peritumoral lymphatic vessels,
thereby endorsing cancer cell diffusion to the regional lymph
nodes and explaining the high propensity of HNSCC for neck
node metastases [55].
Regardless of what the driving force in HNSCC carcino-
genesis may be (HR α-HPV persistent infection or tobacco/
alcohol-related alterations in the expression of oncogenes and
tumor suppressor genes), an unlimited replicative potential
continues to be the hallmark of cancer [56]. The telomere/
telomerase interplay is a key element in determining genomic
stability and cellular replicative potential [57], and both telo-
merase expression/activity and telomere dysfunction have been
extensively investigated in human cancer [57–59] with most
studies indicating that they are crucial, early events in tumori-
genesis often detectable at the precursor lesion stage [60–65].
This review examines current knowledge on the implica-
tions of telomere dysfunction and telomerase up-regulation in
the development and clinical outcome of HNSCC.
2 Telomeres and telomerase: structure
and regulation
2.1 Telomeres
Specialized DNA structures located at the ends of chromo-
somes, telomeres are essential for stabilizing chromosomes
by protecting them from end-to-end fusion and DNA degra-
dation. In human cells, telomeres are composed of
(TTAGGG)n tandem repeats with a 3′ single-stranded over-
hang [66]. Telomeres are associated with capping proteins of
the shelterin complex. Shelterin proteins enable cells to dis-
tinguish their chromosome ends from DNA breaks and to
repress DNA repair reactions as well as to regulate telomere-
based telomere maintenance [67]. Shelterin consists of six
interdependent core subunits: TRF1 and TRF2 (telomeric
repeat-binding factors 1 and 2), TIN2 (TRF1-interacting nu-
clear factor 2), Rap1 (TRF2-interacting protein 1), POT1
(protection of telomeres 1), and TPP1 (POT1 and TIN2-
interacting protein 1) [67]. TRF1 and TRF2 bind the
double-stranded telomeric repeats, whereas POT1 is recruit-
ed to the single-stranded overhang through its specific
single-stranded DNA-binding activity and its interaction
with TPP1. TIN2 tethers TPP1/POT1 to TRF1 and TRF2
[68]. The single-stranded overhang forms the telomeric loop
(T-loop) by invading the double-stranded TTAGG repeats.
T-loop remodeling, which is promoted and maintained by
the members of the shelterin complex, mainly TRF2, pre-
vents the recognition of chromosome ends as sites of
double-strand breaks, thus repressing DNA damage signal-
ing pathways and classical non-homologous end joining at
telomeres or homologous recombination [69]. In particular,
TRF2 represses the ataxia telangiectasia mutated protein
(ATM)-mediated DNA damage signal, while POT1 prevents
the ataxia telangiectasia and Rad3-related (ATR)-mediated
DNA damage response, and both prevent end-to-end telo-
mere fusions [67, 70].
Since DNA polymerase is unable to completely replicate the
3′ end of chromosomes, the loss of telomeric repeats, which
occurs at each round of DNA replication, progressively reduces
telomeres to a critical length [71]. While randomDNA damage
activates a DNA damage response (DDR) until damage is re-
moved, dysfunctional telomeres trigger persistent DDR activa-
tion [72]. Indeed, lacking key shelterin proteins, uncapped telo-
meres trigger a DDR resulting in cell cycle arrest, cellular se-
nescence, and finally apoptosis, mediated by cell checkpoints,
such as p53 and p16INK4a/RB signaling pathways [73].
TRF2 depletion predominantly leads to ATM activation,
whereas deprotection of 3′ single-stranded overhang due to
POT1 depletion activates ATR. ATM and ATR phosphorylate
downstream targets [74], eventually leading to phosphoryla-
tion and p53 activation [75]. p53 induces transcription of the
cyclin-dependent kinase inhibitor p21CIP1 to promote cell cy-
cle arrest [76] and apoptosis by up-regulating several pro-
apoptotic target genes [77].
When p53 and p16INK4a/RB signaling pathways are inac-
tive, cells can bypass senescence and continue to proliferate,
allowing further telomere erosion which leads to increased
genomic instability, including chromosome breakage-fusion-
bridge (BFB) cycles causing structural chromosomal rear-
rangements. This results principally in an additional prolifer-
ative constraint characterized by mitotic catastrophe with
widespread cell death [78]. Telomerase or other mechanisms
of telomere preservation can be stochastically re-activated in
the rare cells that have entered the BFB process. In this sce-
nario, telomeres are maintained and genetically unstable cells
gain immortal growth capacity, a crucial event on the path
towards malignancy [79].
Telomere/telomerase interplay is therefore critical in deter-
mining genomic instability and cellular transformation and, as
such, each seems to be wearing the mask of Janus Bifrons, the
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two-faced Roman god. The consequence of telomere erosion
depends, indeed, on the cellular milieu: in checkpoint-
proficient cells, it leads to tumor suppression by senescence
or apoptosis; while in checkpoint-compromised ones, it leads
to tumor promotion by causing genetic instability (Fig. 1).
2.2 Telomerase
More than 90 % of cancers acquire the capability to replicate
indefinitely through telomerase expression [80], a ribonucleo-
protein complex containing an internal RNA component (TR
or TERC) and a catalytic protein, TERT, with telomere-
specific reverse transcriptase activity [81]. Less than 10 % of
human cancers, typically non-epithelial tumors, preserve their
telomeres by a telomerase-independent alternative lengthen-
ing of telomeres (ALT) pathway [82].
TERT, which synthesizes de novo telomere sequences
using TR as a template, is the rate-limiting component of the
telomerase complex, and its expression is correlated with tel-
omerase activity [81]. Expression of TERT, which is normally
strongly repressed by multiple tumor suppressors and which
plays a critical role in tumor formation and progression, is
essential for unlimited cell growth and is under tight transcrip-
tional control [83]. Regulation of telomerase operates at sev-
eral levels: telomere-associated proteins, in particular TRF1
and POT1, are themselves negative regulators of telomerase
as they repress telomerase access to telomeric ends [84]. Since
longer telomeres contain larger amounts of TRF1, telomere
length is usually maintained at stable average values in
telomerase-expressing cells [85].
TERT gene transcription is probably the key determinant in
telomerase activity regulation; more than 20 transcription
factor-binding sites acting as activators or repressors have
been identified within the TERT promoter. p53, which may
be activated by telomere shortening, binds to transcription
factor Sp1 and renders TERT core promoter inaccessible to
TERT promoter activation in normal somatic cells [86].
Similarly, other cell cycle inhibitors such as p16INK4a [87]
and p27KIP1 [88] may down-regulate TERT expression.
Nuclear factor-kB (NF-kB), hypoxia-inducible factor (HIF)-
1, and the ETS/MYC complex bind to the TERT promoter
thus increasing TERT expression. NF-kB can also induce
TERT translocation from the cytoplasm to the nucleus [89].
TERT promoter activity is also critically dependent on the
chromatin environment and DNA methylation status [90].
SET and MYND domain-containing protein 3 (SMYD3), a
dimethyltransferase and trimethyltransferase, are significantly
up-regulated in several cancers. SMYD3 increases
trimethylation of histone H3-K4 in the TERT promoter, there-
by directly trans-activating the TERT gene [91]. TERT pro-
moter methylation status has unveiled a complex methylation
pattern with some studies reporting hypomethylation in the
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Fig. 1 Short telomeres: senescence and cancer. Telomeres, which are
essential to protect chromosomes from deterioration and from end-to-
end fusion, are specialized DNA structures located at the ends of
chromosomes composed of (TTAGGG)n tandem repeats that are
associated with capping proteins. Human adult somatic cells have a
limited capacity to divide (Hayflick limit) as DNA polymerase alone
cannot replicate the 3′ end of the DNA strand resulting in a progressive
loss of TTAGGG telomeric sequences. Critically short telomeres trigger a
DNA damage response, resulting in cellular senescence, an efficient
tumor suppressor mechanism, and apoptosis. Senescence involves intact
DNA damage checkpoints, such as p53 and p16/RB signaling pathways.
Checkpoint-compromised cells can escape cellular senescence and
apoptosis. In this context, cells can experience an increased number of
divisions and can ultimately enter to breakage-fusion-bridge events and
dramatic genetic instability due to telomere erosion, which most
commonly leads to cell death. Rarely, the cell reactivates telomerase
expression to drive telomere maintenance and replicative immortality.
TERT telomerase reverse transcriptase
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CpG island in the TERT promoter region while others have
described increased DNA methylation in TERT-expressing
cancer cells [80].
Although telomerase’s primary function is telomere elon-
gation and/or maintenance, several different extra-telomeric
functions have also been described. These non-canonical
functions may affect some cellular processes including gene
expression, signaling pathways for the regulation of cell sur-
vival, resistance to stress, and apoptosis [92]. Of interest, the
re-activation of telomerase in cancer cells may affect the can-
cer’s invasiveness and metastasis through the interaction of
TERT with the Wnt/β-catenin [93] and the NF-kB signaling
pathways [94].
In a minority of cases, cancer cells can maintain their telo-
meres by ALT. ALT-mediated telomere elongation is achieved
by telomere recombination between telomere-sister chromatid
exchanges or adjacent chromosomal telomere [95]. The ALT
phenotype is usually characterized by heterogeneous telomere
lengths, the presence of extra-chromosomal telomeric DNA
molecules amassed within ALT-associated promyelocytic leu-
kemia (PML) bodies, and reduced compaction of telomeric
chromatin [96].
3 Telomere dysfunction in HNSCC
In physiological conditions, the stratified squamous epitheli-
um expresses low levels of telomerase activity [97]. Regulated
telomerase activity has indeed been detectable in a subset of
normal transit-amplifying stem cells residing in the basal layer
providing them with an extended proliferative competence
[98]. Consistently, non-cancerous epithelia show basal layers
with longer telomeres with respect to parabasal and suprabasal
ones [64].
Controlled telomerase expression is nevertheless inade-
quate to prevent telomere attrition during aging [99], and telo-
mere shortening and DNA damage accumulate in human stem
cells [100]. Furthermore, during suprabasal differentiation,
telomerase expression is silenced via the recruitment of the
RB-associated histone deacetylase repressor complex to the
−98 E2F site of TERT promoter [101]. All epithelial cells
may experience a progressive shortening of TTAGGG repeats
that eventually results in replicative senescence, a state of
growth arrest which is considered an effective tumor suppres-
sor mechanism [76]. In human oral keratinocytes, senescence
is associated with enhanced expression of discrete gene
groups including G-protein-coupled receptors, matrix metal-
loproteinases (MMP), apolipoproteins, and mitochondrial
proteins [102]. Senescent cells may acquire a senescent-
associated secretory phenotype (SASP) characterized by in-
creased secretion of pro-inflammatory cytokines such as inter-
leukin (IL)-6, IL-1, and IL-8, matrix metalloproteinases, and
reactive oxygen species [103]. SASP may create a pro-
carcinogenic microenvironment in UADT, promoting tumor
development, proliferation, and invasiveness [104].
As stated above, the abrogation of important cell cycle
checkpoints, such as p53 and RB, may allow cells to bypass
replicative senescence and to enter a state of crisis character-
ized by extremely short telomeres which may lead to BFB
cycles and chromothripsis [105].
The presence of anaphase bridges in themajority of HNSCC
is suggestive of their escape from replicative senescence [106].
Supporting the theory that genetic instability in head and neck
carcinogenesis can be triggered by telomere dysfunction, telo-
mere attrition has been associated with BFB events, accumula-
tion of centrosomes, and multipolar cell divisions in cell lines
from benign and malignant head and neck tumors [107, 108].
Also demonstrated in mice models, telomere attrition appears
to be the main driver of genetic instability [109].
Findings indicating that telomere aberrations, mainly
consisting in shortening, are consistently found in HNSCC
precursors and in mucosa surrounding pre-neoplastic areas
and invasive UADT carcinomas [63, 64, 110, 111] support
the hypothesis that genomic instability driven by telomere dys-
function is an early event in the HNSCC oncogenetic process.
Notably, telomere shortening has also been detected in nearby
non-neoplastic esophageal epithelium from patients with inva-
sive esophageal cancer [112] as well as in cancer-associated
normal stromal cells and pre-neoplastic lesions, respectively,
from the prostate [113] and the pancreas [114]. Telomere ero-
sion is thus emerging as a very early, common genetic event in
epithelial carcinogenesis [63]. Remarkably, recent whole-
exome sequencing studies have disclosed that genomic insta-
bility is a dominant feature in HNSCC with about 80 % show-
ing significant chromosomal instability and more than 40 %
exhibiting whole genome duplication [115, 116].
Recently explained in molecular terms, field cancerization
of UADT epithelium [117] offers a unique opportunity to
study the multistep process of carcinogenesis during its earli-
est stages. Telomeres in the epithelium of the UADT from
healthy subjects have been shown to shorten with age [118].
But the lengths of telomeres in histologically normal mucosa
surrounding UADT cancer lesions do not appear to be corre-
lated with patients’ ages, thus suggesting that the epithelium
harbors some proliferative aberrations [63].
Studies examining telomere length in uninvolved, adjacent
epithelium in carcinoma in situ of the oral cavity and in oral
specimens from individuals without HNSCC have demon-
strated that they are significantly shorter and the anaphase
bridges are more abundant in the surrounding tissue of carci-
nomas in situ with respect to those in control specimens [64].
Telomere length analysis of orthokeratotic dysplasia, a precan-
cerous condition frequently associated with SCC and of its
surrounding background tissue, uncovered significantly
shorter telomeres and a higher frequency of BFB with respect
to those in controls [110].
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A substantial number of HNSCC patients have been found
to have extremely short telomeres in histologically normal mu-
cosa surrounding SCC and, even more unexpectedly, short
telomeres in background tissuewere strongly and independent-
ly associated with mucosal failure [63]. It can be inferred from
these findings that SCC arises in a telomere-shortened epithe-
lial field characterized by genetic instability and a prone-to-
transformation status. In this context, telomere shortening can
be considered a biosensor of field cancerization that can iden-
tify patients at risk of local relapses or second field tumors.
Supporting the hypothesis that telomere attrition precedes tel-
omerase re-activation, TERT levels in mucosa surrounding
HNSCC were not correlated with mucosal failure [63].
The amplification or re-activation of telomerase expression
in stem or differentiated cells is considered a key event to
escape crisis and to gain immortalization [97], and telomerase
expression is necessary to convert and maintain an immortal-
ized phenotype in human oral keratinocytes [119].
4 Telomerase in HNSCC
While telomerase activity is detectable in most tumors, it is
usually absent in normal somatic cells [66]. Telomerase activ-
ity can be measured by means of polymerase chain reaction
(PCR)-based telomere-repeat amplification protocol (TRAP),
by scoring immunohistochemical TERT staining or by quan-
tifying TERT mRNA using real-time PCR [81, 120, 121].
When real-time PCR or TRAP have been utilized, weak
telomerase expression and activity have frequently been found
in normal UADTepithelium [61, 63, 122–136]. High levels of
telomerase expression have been detected in as much as 75–
100 % of HNSCC [111, 126–128, 130–135, 137–148].
According to in vitro studies, telomerase is induced in a sub-
stantial proportion of HNSCCs in telomerase-deficient
keratinocytes and not by telomerase overexpression in
telomerase-positive cells. This can be inferred by the high
anaphase bridge index, dicentric chromosomes, and multipo-
lar spindles, which indicate that these cells have experienced a
period of critically shortened TTAGGG repeats before telo-
merase re-activation [106, 107]. Telomerase re-activation or
up-regulation can be achieved by gene amplification, promot-
er mutations, TERT mRNA alternative splicing, epigenetic
changes, or through post-translational processing [97].
Liu et al. [149] reported that TR amplification was one of
the most frequent amplifications observed in laryngeal SCC
with the rate rising progressively with the increasing severity
of the lesions: none were, indeed, found in normal epithelium
and 100% in invasive cancer. Telomerase activity, however, is
strictly correlated with TERT levels, while higher TR levels
do not affect its catalytic properties [81, 150]. Comprehensive
genomic characterization of HNSCC has frequently uncov-
ered amplification of chromosome 5p, which encompasses
TERT gene, in both HPV-positive and HPV-negative carcino-
mas [42, 151].
TERT promoter is transcriptionally silenced upon cellular
differentiation. In cancer cells, TERT expression is induced by
several cellular transcription factors including NF-kB [152],
β-catenin [153], and c-Myc [154]. Conversely, wild-type
TP53 down-regulates TERT by forming a complex with the
transcription activator Sp1 and, thus, inhibiting Sp1 binding to
the TERT proximal promoter [86].
HR α-HPV E6 oncoprotein contributes to cell immortali-
zation and transformation through both p53 degradation and
telomerase activation. HPV-driven oropharyngeal SCCs ex-
press very high TERT levels [63]. The mechanisms underly-
ing telomerase activation by E6 viral oncoprotein have not
been completely elucidated. E6 can indirectly increase TERT
expression by inducing p53 degradation. Furthermore, the in-
crease in telomerase expression and activity in HPV-
transformed cells could be the effect of E6-induced TERT
transcription or post-transcriptional mechanisms. E6 from
HR α-HPV can activate telomerase via degradation of
NFX1-91, a transcription repressor of TERT [155]. In addi-
tion, HPV16 E6 physically and functionally interacts with
telomerase complex and increases TERT catalytic activity
[53]. Latent membrane protein 1 (LMP1) of Epstein–Barr
virus may activate TERT via NF-kB and MAPK/ERK1/2
[156, 157]. In EBV-associated nasopharyngeal carcinoma,
LMP1 enhances TERT expression and phosphorylation
through the PI3K/AKT signaling pathway, and this makes
the cells more resistant to irradiation [157].
Very recently, two prevalent and mutually exclusive mu-
tations in the promoter of TERT (228C>T and 250C>T)
emerged as the most frequently observed non-coding muta-
tions in cancer and were associated with high levels of tel-
omerase in multiple cancer types [158]. Notably, these mu-
tations specifically promote TERT expression in telomerase-
negative differentiated cell compartments, while their impact
in telomerase-positive stem cell reservoirs appears to be neu-
tral [150]. Thus, TERT promoter mutations uncouple cellular
differentiation and telomerase silencing. These mutations re-
sult in generating de novo binding sites for transcription
factors of the E26 transformation-specific family (ETS). In
particular, the ETS GA-binding protein transcription factor α
subunit selectively links the mutant form of the TERT pro-
moter and increases TERT transcriptional activity [159].
More common in tumors derived from cells with low self-
renewal rates, TERT promoter mutations have also been de-
tected in a significant proportion of oral tongue [44, 45] and
laryngeal SCCs [46]. SCCs of the base of the tongue, which
are usually HPV-related, harbor, instead, wild-type TERT
promoter [44]. HR α-HPV infection and TERT promoter
mutations may be alternative mechanisms to up-regulate tel-
omerase in HNSCC [44]. Remarkably, 228C > T and
250C>T mutations in the TERT promoter are more frequent
Cancer Metastasis Rev
in laryngeal tumors in smokers compared to that in non-
smokers and are independently associated with poor overall
survival (OS) [46].TERT promoter activity can be modified
by a common polymorphism within the preexisting ETS2
binding site in the TERT promoter with patients with the
rs2736098 variant and in particular those exposed to tobacco
and alcohol having a lower risk of SCC of the oropharynx
[160].
As histone deacetylase inhibitor FR901228 induces a
significant increase in TERT expression in oral cancer
cell lines, it is possible that the latter is epigenetically
controlled in HNSCC through changes in DNA meth-
ylation or histone acetylation [161]. TERT regulation
can also occur via post-translational protein modifica-
tion [162]. Specific protein kinase C isoenzymes,
namely α, β, δ, ɛ, and ζ (over-expressed in this ma-
lignancy), in HNSCC have been shown to regulate tel-
omerase activity by phosphorylating TERT. This phos-
phorylation results in the interaction of telomerase and
chaperone protein hsp90, an essential step for telome-
rase holoprotein integrity and enzymatic activity [163].
As telomerase expression is found in a large fraction
of HNSCC, a subgroup of these tumors does not seem
to require telomerase to maintain telomere, although
the presence of Taq polymerase inhibitors and RNA
degradation during specimen collection and processing
cannot be excluded [133]. Human laryngeal cancer cell
lines that survive after transfection with RNAi plasmid
targeting TERT sequence show sustained proliferation
and the presence of PML bodies suggesting that they
are capable of employing an ALT pathway to maintain
their telomeres [164]. This finding may pose a chal-
lenge if telomerase inhibitors are used to treat HNSCC.
As far as UADT pre-neoplastic lesions are concerned,
telomerase expression is positively correlated with their
severity in both oral and laryngeal SCC [122, 123, 134,
146, 147, 149, 165]. Interestingly, oral verrucous leukopla-
kia, an aggressive, premalignant lesion, exhibits telome-
rase activity levels approaching those found in invasive
oral SCC [129]. Telomerase can be associated, alone or
together with other markers, with a more aggressive phe-
notype and behavior in HNSCC. Several studies have, in-
deed, reported that TERT mRNA levels and telomerase
activity are higher in poorly differentiated SCC [63, 126,
143, 146, 166–169], increase with tumor stage [63, 131,
142, 166], and are associated with lymph node involve-
ment [63, 126, 131, 137, 139, 170] or extracapsular exten-
sion of lymph node metastases [125]. Numerous studies
have analyzed telomerase’s ability to predict outcome
(Table 1) [46, 63, 125, 127, 130, 136, 139, 140, 144,
171–177], and most have reported a correlation between
increased telomerase expression and activity and a reduced
response to treatment and a higher rate of regional and
distant metastases ultimately resulting in poor clinical out-
come [63, 125, 127, 136, 144, 171, 173–176]. A study
examining a large sample of neoplastic tissues from 217
HNSCC patients reported that telomerase activity was an
independent predictor of poor survival after adjustment
was made for age, site, stage, histological grade, tumor
depth, and extracapsular extension [125]. These results
have been corroborated by studies focusing on other ma-
lignancies that have shown that telomerase activity corre-
lates with progression and poor prognosis in lung [60],
colorectal [62], breast [178], and prostate [179] cancers.
These data are consistent with previous experimental ob-
servation and studies using in vivo mouse models demon-
strating that a systemic injection of anti-telomerase ribo-
zyme inhibiting telomerase activity significantly reduces
metastatic progression in tumor-bearing mice [180, 181].
The associations between high telomerase expression and
activity and more aggressive phenotypes and progression in
HNSCC may be ascribable not only to its ability to maintain
telomere lengths in rapidly proliferating cells but also to
TERT’s extra-telomeric functions and their interactions with
other cancer-related signaling cascades, such as Wnt/β-caten-
in and NF-kB pathways [92, 182]. TERT’s extra-telomeric
functions are implicated in regulating several cancer hall-
marks including cell proliferation, angiogenesis, invasion,
and metastasis [57]. Sustaining the roles of telomerase non-
canonical functions in tumor invasiveness and progression in
HNSCC, the instauration of ALT mechanisms to elongate
telomeres in laryngeal cancer cells following telomerase inhi-
bition, while maintaining a transformed phenotype, has been
associated with less aggressive tumor features [164].
The Wnt/β-catenin pathway is a crucial regulator of the
self-renewal property of normal amplifying adult stem cells,
and its deregulation plays a critical role in abnormal cell pro-
liferation and oral oncogenesis [183, 184]. Activation of the
canonical Wnt signaling pathway results in the stabilization
and nuclear translocation of β-catenin. In the absence of Wnt
stimulus, cytoplasmic β-catenin is constantly targeted to the
proteasome by the multiprotein destruction complex, which
includes protein kinases CK1γ and GSK3β [185]. When ac-
tivated, the Wnt/β-catenin pathway results in increasingly
higher levels of β-catenin that eventually move to the nucleus
and interact with LEF/TCF transcription factors thus promot-
ing the transcription of target genes such as MYC and cyclin
D1 [186]. Epithelial-to-mesenchymal transition (EMT), an es-
sential step in cancer invasiveness and metastatic dissemina-
tion which is characterized by loss of cell-cell adhesion and
the acquisition of migratory properties, is regulated by several
proteins including β-catenin and vimentin [187]. TERT can
stimulate the EMT program and induce an undifferentiated
stem-like phenotype, a process associated with β-catenin sig-
naling activation [93]. TERT binds β-catenin thus preventing
its degradation, enhancing its nuclear accumulation and
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transcriptional activity, and regulates vimentin transcription in
cooperation with β-catenin [93]. It has recently been observed
that the overexpression of TERT in oral SCC is sufficient to
induce a mesenchymal phenotype, and this is strictly related
to the activation of the Wnt/β-catenin pathway. Silencing
TERT, instead, leads to the inhibition of Wnt/β-catenin signal-
ing and the suppression of EMT in oral cancer [188].
Interestingly, β-catenin is a known activator of TERT expres-
sion [153].
The NF-kB pathway regulates the expression of sev-
eral genes including those involved in cellular prolifera-
tion, differentiation, and apoptosis. NF-kB is constitu-
tively expressed in HNSCC and plays a crucial role as
the modulator of the gene expression program associated
with maintaining the malignant phenotype, invasiveness,
and metastasis in SCC [189, 190]. It has been established
that NF-kB regulates TERTexpression by binding to a site 350-
bp upstream from the translational start site. TERT nevertheless
directly interacts with the NF-kB p65 subunit and regulates the
expression of NF-κB target genes, such as IL-6, tumor necrosis
factor (TNF)-α, IL-8, MMP9, commonly over-expressed in
HNSCC [191]. IL-6 and IL-8 both induce EMT and promote
metastasis in HNSCC via activation, respectively, of JAK-
STAT3-SNAIL and AKT signaling pathways [192, 193]. In
addition to IL-6, TNF-α also converges upon STAT3 up-
regulating it. Moreover, TNF-α increases cell motility, migra-
tion, and invasion of human hypopharyngeal cancer cells by
inducing TWIST expression, a basic helix-loop-helix transcrip-
tion factor and dominant regulator of the EMT program in
many solid tumors [194]. Some have hypothesized that TERT
provides oral cancer cells with invasion capability by modulat-
ing cathepsin D,MMP2, andMMP9which, in turn, degrade the
extracellular matrix and collagen IV, essential for basement
membrane stability and integrity [195].
HPV-driven oropharyngeal SCCs show a higher propensity
for lymph node metastasis with respect to their HPV-negative
counterparts and are not uncommonly characterized by an atyp-
ical pattern of distant metastases [6]. Preliminary data have
shown that these malignancies may express extremely elevated
TERT levels [63]. It can be speculated that the consequent in-
crease in telomerase’s extra-telomeric functionsmay be related to
this clinical behavior. TERT may, thus, be strictly involved in
regulating critical SCC-related pathways, such as Wnt/β-catenin
and NF-kB signaling, in a feed-forward loop context that am-
plifies and sustains autonomous cancer cell proliferation and tu-
mor progression (Fig. Fig. 2).
5 Telomere length in peripheral blood mononuclear
cells (PBMC) and risk of HNSCC
As telomere length shortens with age, the parameter can be
used as a marker of biological aging. But the high rate of inter-
individual variations in telomere length among age-matched
peers [196] appears to suggest that it reflects an individual risk
for age-related diseases and cancer [197]. As telomere lengths
in PBMC are strongly correlated with those in cells of differ-
ent tissues, they are considered a surrogate marker for other
tissues [198]. In cancer epidemiological investigations, telo-
mere lengths in PBMC are usually determined to estimate the
correlation between biological aging and cancer risk.
The role of telomere length in PBMC and cancer risk is quite
controversial depending on the tumor type and the familial or
sporadic context. Nevertheless, as suggested by Zhang et al. [58],
various neoplasms show intrinsic biological heterogeneity, and
different biological pathways may be modulated in various ways
by telomere status. Telomere shortening in PBMC could be con-
sidered a biosensor of endogenous and environmental damage:
factors increasing oxidative stress, e.g., cigarette smoking, are
associated with telomere shortening in PBMC, while telomere
erosion is, in turn, a driver of genetic instability which may
promote tumorigenesis [58, 199, 200].
One large case–control study did not find a significant asso-
ciation between telomere length in PBMCs and HNSCC risk
[201]. Conversely, two recently published case–control studies
[202, 203] confirmed the results obtained a decade ago by Wu
et al. [204] showing that telomeres were significantly shorter in
PBMCs in HNSCC patients with respect to those in controls.
When 266 patients with oral premalignant lesions or oral SCCs
were compared with 394 age- and sex-matched controls, short-
ened telomeres were found to be an independent risk factor in
PBMCs, although the risk was considerably higher in tobacco
and alcohol consumers [202]. Telomere length also appeared to
influence the malignant progression of pre-neoplastic lesions of
the oral cavity. Short telomeres in PBMC may constitute an
additional biomarker of oral habits and thus help to identify
subjects at high risk of HNSCC. In another study [203] examin-
ing the association between telomere length in PBMCs and the
risk of HR α-HPV-associated oropharyngeal SCC, the authors
reported that short telomeres appeared to synergize with HPV
type 16, increasing the risk of oropharyngeal SCC, particularly in
the younger never smoker/drinker subgroup.
6 Telomerase in the peripheral blood compartment:
can liquid biopsies be used as potential biomarkers
for HNSCC?
Circulating tumor cells and tumor-driven nucleic acids, such
as circulating cell-free DNA and RNA, could be useful in
detecting real-time tumor dynamics and in monitoring drug
sensitivity during treatment.
Telomerase expression and activity in the peripheral
blood compartment of HNSCC patients has been estimat-
ed in PBMCs or quantified by measuring circulating cell-
free TERT mRNA by some studies.
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The rate of telomerase activity in PBMCs has been found to
be significantly higher in HNSCC patients with respect to that
in healthy controls and associated with advanced stage, lymph
node metastases, and poor overall survival (OS) [205, 206].
Two mechanisms have been hypothesized to explain this find-
ing [205]. First, PBMC could be activated by soluble factors,
secreted either by the cancer or by the tumormicroenvironment.
Mean serum vascular endothelial growth factor levels have,
indeed, been significantly linked with telomerase activity in
PBMCs in HNSCC patients [207]. Alternatively, PBMC could
be activated after tumor antigen processing and cross-
presentation has taken place in draining lymph nodes.
Several authors have reported higher TERT mRNA
plasma levels in cancer patients with respect to those in
controls, and a correlation has been found between circu-
lating TERT levels and more severe clinical-pathological
features and disease outcomes [208–210]; thus, circulat-
ing TERT could be considered a noninvasive tool for de-
tecting cancers and monitoring the course of treatment. To our
knowledge, the only study that has investigated the significance
of TERTmRNAplasma levels in HNSCC patients reported that
the values were indeed significantly elevated before surgery
and that they decreased significantly two days after surgery
[211]. Additional studies are clearly warranted to verify the
feasibility of using cell-free circulating plasma TERT mRNA
to diagnose the carcinoma early and to monitor treatment re-
sponse in these patients.
7 Conclusions
Although telomere dysfunction and telomerase activa-
tion appear to be dynamic processes during epithelial
carcinogenesis, studies carried out until now have
attempted to photograph them at a single point in time
and have been unable to capture their mutable complex
interaction. Our understanding of the complicated
telomere/telomerase interplay in human cancer remains,
in fact, for the time being incomplete. In the light of the
comprehensive review of recently performed studies
presented here, some conclusions can, however, be
drawn about the clinicopathological and prognostic sig-
nificance of telomere status and telomerase activity in
HNSCC (Box 1).
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Fig. 2 Epithelial carcinogenesis and telomere/telomerase interplay. The
inactivation of the p53 and RB pathways are the main molecular
determinants in head and neck carcinogenesis. In tobacco- and alcohol-
related HNSCC, the abrogation of p53 and RB pathways may occur via
mutation and genetic/epigenetic alterations. In HPV-driven carcinomas,
p53 and RB pathways are inactivated at the protein level by E6 and E7
HR α-HPV oncoproteins, respectively. In this context, cells can bypass
cellular senescence (a condition triggered by telomere shortening in
which cells remain viable but are unable to divide) and experience an
increased number of cell divisions of potentially premalignant clones
characterized by extremely shortened telomeres and genetic instability.
Different strategies may lead to re-activation of telomerase, a
ribonucleoprotein complex containing an internal RNA component and
a catalytic protein, TERT, with telomere-specific reverse transcriptase
activity which synthesizes de novo telomere sequences. Cells can thus
escape from apoptosis and maintain short but stable telomere lengths
which are the key to cell immortality. Besides providing cells with
unlimited proliferation potential, telomerase interacts with other cancer-
related signaling cascades, such as Wnt/β-catenin and NF-kB pathways.
In this scenario, telomerase plays additional non-canonical roles that may
impact cancer progression by inducing crucial factors, such as MMP9,
TNF-α, IL-6, and activating cellular programs leading to increased tumor
cell motility/migration/invasion capability and epithelial-to-
mesenchymal transition, in a context of feed-forward loops. HR α-HPV
high-risk alpha human papillomaviruses, TERT telomerase reverse
transcriptase, NF-kB nuclear factor-kB, EMT epithelial-to-mesenchymal
transition,MMPmatrix metalloproteinase, TNF tumor necrosis factor, RB
protein retinoblastoma
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Box 1. Key findings regarding telomeres and telomerase in
HNSCC
• HNSCC precursors and normal mucosa surrounding pre-neoplastic areas
and invasive carcinomas are characterized by shortened telomeres.
• Short telomere lengths in mucosa surrounding HNSCC are strongly
prognostic of mucosal failure.
• Short telomere lengths in normal mucosa surrounding HNSCC can be
considered a marker of “field cancerization.”
• Telomerase activation plays a role in the majority of HNSCC cases.
• The timing of telomerase expression and activation may differ
depending on the genetic and epigenetic context.
• Telomerase activity, which increases with tumor progression, is a
prognostic marker of regional and distant failure.
• The significance of telomere length and telomerase activity in peripheral
blood cells and of circulating TERT mRNA levels in the plasma of
patients with HNSCC are complex issues warranting further studies
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Analysis of SCC precursors and the normal mucosa sur-
rounding pre-neoplastic and neoplastic areas has uncovered
that extremely short telomeres are independently associated
with mucosal failure and, thus, could represent potential bio-
markers identifying patients at risk for relapses.
Several studies have shown that TERT mRNA levels and
telomerase activity in HNSCC, which are associatedwith poor
outcomes, gradually rise commensurately with the degree of
epithelial aberrations and disease aggressiveness.
In conclusion, telomere/telomerase interplay and telomere
shortening warrant further investigation in view of their ability
to stratify HNSCC patients and the implications that they have
on treatment and follow-up strategies in this particular patient
population (Box 2).
Box 2. Questions that are still open with regard to telo-
meres and telomerase’s roles in the development of HNSCC
• Are the mechanisms, significance, and effects of telomerase re-activation
different in HPV-negative with respect to HPV-driven HNSCC?
• Are shortened telomeres in normal mucosa adjacent to HNSCC the
consequence of greater cell proliferation or are they linked to an
individual’s constitutive telomere length?
• How does telomerase interact and cooperate with other cancer-related
intracellular signaling pathways in head and neck tumorigenesis?
• Are telomerase’s non-canonical functions critical for cancer invasion
and metastasis HNSCC?
• What is the significance of telomere length in peripheral blood
mononuclear cells?
• Is cell-free circulating plasma TERT mRNA a useful marker in diag-
nosing HNSCC and monitoring of treatment response?
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